Seroatlas · Human Serome Atlas

SLC2A9

Solute carrier family 2, facilitated glucose transporter member 9

Also known as: Glut9, GLUTX, GTR9_HUMAN, URATv1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NRM0
Gene: SLC2A9
Ensembl: ENSG00000109667
Chromosome: 4
Canonical length: 540 aa
Protein class: Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene encodes a member of the SLC2A facilitative glucose transporter family. Members of this family play a significant role in maintaining glucose homeostasis. The encoded protein may play a role in the development and survival of chondrocytes in cartilage matrices. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

540 residues, UniProt reviewed canonical sequence.

>Q9NRM0|SLC2A9
     1  MARKQNRNSK ELGLVPLTDD TSHAGPPGPG RALLECDHLR SGVPGGRRRK DWSCSLLVAS
    61  LAGAFGSSFL YGYNLSVVNA PTPYIKAFYN ESWERRHGRP IDPDTLTLLW SVTVSIFAIG
   121  GLVGTLIVKM IGKVLGRKHT LLANNGFAIS AALLMACSLQ AGAFEMLIVG RFIMGIDGGV
   181  ALSVLPMYLS EISPKEIRGS LGQVTAIFIC IGVFTGQLLG LPELLGKEST WPYLFGVIVV
   241  PAVVQLLSLP FLPDSPRYLL LEKHNEARAV KAFQTFLGKA DVSQEVEEVL AESRVQRSIR
   301  LVSVLELLRA PYVRWQVVTV IVTMACYQLC GLNAIWFYTN SIFGKAGIPP AKIPYVTLST
   361  GGIETLAAVF SGLVIEHLGR RPLLIGGFGL MGLFFGTLTI TLTLQDHAPW VPYLSIVGIL
   421  AIIASFCSGP GGIPFILTGE FFQQSQRPAA FIIAGTVNWL SNFAVGLLFP FIQKSLDTYC
   481  FLVFATICIT GAIYLYFVLP ETKNRTYAEI SQAFSKRNKA YPPEEKIDSA VTDGKINGRP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC2A9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 12
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 27 nTPM

Expression across tissuesHPA

Tissue

kidney: 27 nTPM
liver: 20 nTPM
seminal vesicle: 18 nTPM
salivary gland: 15 nTPM
duodenum: 10 nTPM
small intestine: 8 nTPM

Single-cell type

proximal tubule cells: 1,695 nCPM
cone photoreceptor cells: 174 nCPM
somatotrophs: 148 nCPM
epididymal basal cells: 146 nCPM
medullary thymic epithelial cells: 137 nCPM
salivary myoepithelial cells: 116 nCPM

Immune cell

classical monocyte: 37 nTPM
myeloid DC: 31 nTPM
plasmacytoid DC: 12 nTPM
total PBMC: 9.1 nTPM
intermediate monocyte: 7.6 nTPM
neutrophil: 1.1 nTPM

Brain region

white matter: 5.9 nTPM
choroid plexus: 5.4 nTPM
medulla oblongata: 4.7 nTPM
thalamus: 4.1 nTPM
spinal cord: 3.7 nTPM
pons: 3.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC2A9.

Disease | AllUniProt

Conditions SLC2A9 is implicated in, by any mechanism.

Hypouricemia renal 2 (RHUC2) MIM:612076

Disease | GeneticClinVar

21 pathogenic / likely-pathogenic of 331 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Hypouricemia, renal, 2
SLC2A9-related disorder
Renal tubulopathies

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.14
gnomAD pLI: 0
gnomAD missense Z: -0.12
DepMap mean gene effect: 0.12
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC2A9 as an antibody target. Whether an autoantibody or antibody against SLC2A9 could matter depends on whether native SLC2A9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC2A9 is annotated at the cell surface, where native SLC2A9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC2A9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...